Precancerous Cervical Lesion Among Adult Women With Human Immune Deficiency Virus on Anti Retroviral Therapy At Saint Peter Specialized Hospital, Ethiopia: A Hospital-Based Cross-Sectional Study.
ART
Ethiopia
HIV
precancerous cervical lesion
prevalence
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
04
2022
accepted:
31
05
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Cervical cancer is the fourth most frequent cancer in women representing 6.6% of all female cancers occurring in low and middle-income countries, where resources for cancer prevention programs are often scarce. So this study aimed to assess the prevalence of precancerous cervical lesion and associated factors among adult women with human immune deficiency virus (HIV) on Anti Retroviral Therapy (ART) at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia. An institution-based cross-sectional study was conducted from November 06 to July 20, 2020 among 267 adult women with HIV on Anti Retroviral Therapy At Saint Peter Specialized Hospital, Ethiopia. Data were collected using face-to-face interview, patient chart review, and the examination of the squamo-columnar junction by the visual inspection with the acetic acid method. The collected data were entered into Epi-data version 3.1 and exported to Statistical Package for the Social Sciences (SPSS) version 24.0 for analysis. Bivariate and multivariable binary logistic regression analysis were used to identify factors associated with the precancerous cervical lesion. Statistical significance was considered at a P-valve less than 0.05. A total of 267 women who were on ART were included in the study and the prevalence of precancerous cervical lesion was 7.5% with 95% CI =4.10%-10.50%. Modern family planning (AOR = 4.14, 95% CI = 1.23-13.87), history of sexual transmission infection (STI) (AOR=5.39, 95% CI= 1.56-18.70) and viral load (AOR=20.85, 95% CI = 6.19-70.25) had significant association with precancerous cervical lesion. In this study, the prevalence of precancerous cervical lesion is relatively low compared to studies in low and middle-income countries. Modern family planning, history of sexual transmitted infection, and viral load had a significant association with a precancerous cervical lesion. Hence, encouraging modern family planning, and routine screening of women for pre-cancerous cervical lesions for those with high viral load have enormous contributions to decreasing cervical cancer disease among Women with Human Immune Deficiency Virus through Anti Retroviral Therapy.
Sections du résumé
Background
UNASSIGNED
Cervical cancer is the fourth most frequent cancer in women representing 6.6% of all female cancers occurring in low and middle-income countries, where resources for cancer prevention programs are often scarce. So this study aimed to assess the prevalence of precancerous cervical lesion and associated factors among adult women with human immune deficiency virus (HIV) on Anti Retroviral Therapy (ART) at Saint Peter Specialized Hospital, Addis Ababa, Ethiopia.
Methods
UNASSIGNED
An institution-based cross-sectional study was conducted from November 06 to July 20, 2020 among 267 adult women with HIV on Anti Retroviral Therapy At Saint Peter Specialized Hospital, Ethiopia. Data were collected using face-to-face interview, patient chart review, and the examination of the squamo-columnar junction by the visual inspection with the acetic acid method. The collected data were entered into Epi-data version 3.1 and exported to Statistical Package for the Social Sciences (SPSS) version 24.0 for analysis. Bivariate and multivariable binary logistic regression analysis were used to identify factors associated with the precancerous cervical lesion. Statistical significance was considered at a P-valve less than 0.05.
Result
UNASSIGNED
A total of 267 women who were on ART were included in the study and the prevalence of precancerous cervical lesion was 7.5% with 95% CI =4.10%-10.50%. Modern family planning (AOR = 4.14, 95% CI = 1.23-13.87), history of sexual transmission infection (STI) (AOR=5.39, 95% CI= 1.56-18.70) and viral load (AOR=20.85, 95% CI = 6.19-70.25) had significant association with precancerous cervical lesion.
Conclusion
UNASSIGNED
In this study, the prevalence of precancerous cervical lesion is relatively low compared to studies in low and middle-income countries. Modern family planning, history of sexual transmitted infection, and viral load had a significant association with a precancerous cervical lesion. Hence, encouraging modern family planning, and routine screening of women for pre-cancerous cervical lesions for those with high viral load have enormous contributions to decreasing cervical cancer disease among Women with Human Immune Deficiency Virus through Anti Retroviral Therapy.
Identifiants
pubmed: 35957869
doi: 10.3389/fonc.2022.910915
pmc: PMC9361014
doi:
Types de publication
Journal Article
Langues
eng
Pagination
910915Informations de copyright
Copyright © 2022 Zelalem, Weldegebreal, Ayele, Deressa, Debella, Eyeberu, Hassen and Dessie.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Braz J Infect Dis. 2012 Mar-Apr;16(2):164-9
pubmed: 22552459
BMC Res Notes. 2018 Feb 20;11(1):145
pubmed: 29463299
Int J Health Sci (Qassim). 2019 May-Jun;13(3):4-9
pubmed: 31123433
BMC Cancer. 2015 Jul 24;15:541
pubmed: 26205980
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:28-44
pubmed: 34669203
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Clin Pathol. 2015 Sep 23;15:16
pubmed: 26401120
Infect Agent Cancer. 2019 Nov 11;14:36
pubmed: 31737087
AIDS Res Treat. 2012;2012:953743
pubmed: 22548156
J Oncol. 2016;2016:5473681
pubmed: 27478441
PLoS One. 2018 Jan 19;13(1):e0191506
pubmed: 29352278
Ethiop Med J. 2015 Jul;Suppl 2:17-24
pubmed: 26591279
BMC Public Health. 2013 Jun 14;13:582
pubmed: 23767681
Pan Afr Med J. 2022 Apr 06;41:276
pubmed: 35784594
Int J Cancer. 2017 Apr 15;140(8):1850-1859
pubmed: 28108997